Real-world utilization pattern of pexidartinib in patients with tenosynovial giant cell tumor (TGCT)

被引：0
|
作者：
Lin, Feng
Tse, Jenny
Shaikh, Nazneen Fatima
Wang, Elizabeth J.
Near, Aimee
Kwong, Jackie
Tap, William D.
机构：
[1] Daiichi Sankyo Inc, Basking Ridge, NJ USA
[2] IQVIA, Durham, NC USA
[3] Mem Sloan Kettering Canc Ctr, Sarcoma Med Oncol Serv, 1275 York Ave, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e18792
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Population Pharmacokinetic Analysis of Pexidartinib in Healthy Subjects and Patients With Tenosynovial Giant Cell Tumor or Other Solid Tumors
    Yin, Ophelia
    Wagner, Andrew J.
    Kang, Jia
    Knebel, William
    Zahir, Hamim
    van de Sande, Michiel
    Tap, William D.
    Gelderblom, Hans
    Healey, John H.
    Shuster, Dale
    Stacchiotti, Silvia
    JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 61 (04): : 480 - 492
  • [22] Pexidartinib (TURALIO™): The First FDA-Indicated Systemic Treatment for Tenosynovial Giant Cell Tumor
    Monestime, Shanada
    Lazaridis, Dovena
    DRUGS IN R&D, 2020, 20 (03) : 189 - 195
  • [23] Drug-Induced Liver Injury Associated With Pexidartinib Treatment for Tenosynovial Giant Cell Tumor
    Peraza, Jellyana
    Rahman, Shafia
    Yibirin, Marcel
    De Oliveira, Diana
    Mekaiel, Andrew
    Chai, Jiani
    Hoang, Bang
    Yang, Rui
    Geller, David
    Frager, Shalom Z.
    Paoluzzi, Luca
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S1120 - S1121
  • [24] Clinical benefit of imatinib in patients with relapsed tenosynovial giant cell tumor/ pigmented villonodular synovitis (TGCT/PVNS).
    Yu, Jeanette Cu
    Sidhu, Manpreet Kaur
    Fang, Andrew
    Morse, Lee Jae
    Pan, Minggui
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [25] Pexidartinib in the Management of Advanced Tenosynovial Giant Cell Tumor: Focus on Patient Selection and Special Considerations
    Vaynrub, Anna
    Healey, John H.
    Tap, William
    Vaynrub, Max
    ONCOTARGETS AND THERAPY, 2022, 15 : 53 - 66
  • [26] Pexidartinib (TURALIO™): The First FDA-Indicated Systemic Treatment for Tenosynovial Giant Cell Tumor
    Shanada Monestime
    Dovena Lazaridis
    Drugs in R&D, 2020, 20 : 189 - 195
  • [27] Pexidartinib Upfront in a Case of Tenosynovial Giant Cell Tumor: Proof of Concept for a Treatment Paradigm Shift
    Palmerini, Emanuela
    Peta, Giuliano
    Tuzzato, Gianmarco
    ONCOLOGY AND THERAPY, 2024, 12 (04) : 833 - 841
  • [28] CORR Insights®: Pexidartinib Provides Modest Pain Relief in Patients With Tenosynovial Giant Cell Tumor: Results From ENLIVEN
    Damron, Timothy A.
    CLINICAL ORTHOPAEDICS AND RELATED RESEARCH, 2023, 481 (01) : 117 - 119
  • [29] Final results of ENLIVEN: A global, double-blind, randomized, placebo-controlled, phase 3 study of pexidartinib in advanced tenosynovial giant cell tumor (TGCT).
    Tap, William D.
    Gelderblom, Hans
    Stacchiotti, Silvia
    Palmerini, Emanuela
    Ferrari, Stefano
    Desai, Jayesh
    Bauer, Sebastian
    Blay, Jean-Yves
    Alcindor, Thierry
    Ganjoo, Kristen N.
    Broto, Javier Martin
    Ryan, Christopher W.
    Shuster, Dale Edward
    Zhang, Ling
    Wang, Qiang
    Hsu, Henry
    Lin, Paul S.
    Tong, Sandra
    Wagner, Andrew J.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [30] Pexidartinib for advanced tenosynovial giant cell tumor (TGCT): Long-term efficacy and safety from the phase 3 ENLIVEN and phase 1 PLX108-01 (TGCT cohort) studies.
    Gelderblom, Hans
    Tap, William D.
    Palmerini, Emanuela
    Stacchiotti, Silvia
    Wainberg, Zev A.
    Desai, Jayesh
    Healey, John H.
    van de Sande, Michiel
    Bernthal, Nicholas M.
    Peterfy, Charles
    Shuster, Dale Edward
    Wang, Qiang
    Hsu, Henry
    Wagner, Andrew J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345